The US Special Operations Command (SOCOM) will soon begin clinical trials of an anti-aging drug for 2022, according to an article in Breaking Defense magazine (www.breakingdefense.com).
SOCOM has funded $2.8m in a joint effort with private biotechnology company Metro International Biotech LLC (Metro Biotech) to develop this drug-pill.
According to the article, SOCOM has completed the pre-clinical safety and “dosing” studies, pending the next performance tests of the drug, which could “delay aging” and help with injuries.
SOCOM’s goal is to accelerate and improve the existing performance characteristics of its executives and members which decline over time.
Such features are improved human performance such as increased endurance and recovery from injury.
Such an invention in the field of biotechnology is very encouraging because later any success in the military will be given for widespread use to civilians.
